Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
OGN · NYSE · United States · Pharmaceutical Preparations
In shortOrganon & Co. is profitable, generates cash and carries heavy debt, with revenue shrinking (−2.9% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 3.0% | 32/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 30.6% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.82× | 85/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 11.49× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 8.7% | 55/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 2.88× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 2.6% | 100/100 |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
| Revenue growth, 3-year average | 0.2% | 18/100 |
|---|---|---|
| EPS growth, 3-year average | -41.5% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 6,304 | 6,174 | 6,263 | 6,403 | 6,216 |
| Cost of revenue | 2,382 | 2,294 | 2,515 | 2,688 | 2,903 |
| Gross profit | 3,922 | 3,880 | 3,748 | 3,715 | 3,313 |
| Research & development | 443 | 471 | 528 | 469 | 366 |
| Selling, general & admin | 1,668 | 1,704 | 1,893 | 1,760 | 1,721 |
| Interest expense | 258 | 422 | 527 | 520 | 504 |
| Pre-tax income | 1,529 | 1,122 | 673 | 807 | 425 |
| Income tax | 178 | 205 | (350) | (57) | 238 |
| Net income | 1,351 | 917 | 1,023 | 864 | 187 |
| Diluted EPS | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Diluted shares (millions) | 254 | 255 | 256 | 259 | 261 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 31, 2026